Literature DB >> 11493668

Functional interaction between the SSeCKS scaffolding protein and the cytoplasmic domain of beta1,4-galactosyltransferase.

M J Wassler1, C I Foote, I H Gelman, B D Shur.   

Abstract

The beta1,4-galactosyltransferase family contains at least seven unique gene products, of which beta1,4-galactosyltransferase I (GalT) is the most exhaustively studied. GalT exists in the Golgi complex, similar to many other glycosyltransferases, as well as on the cell surface, where it functions as a signaling receptor for extracellular glycoside ligands. When expressed on the surface, GalT associates with the cytoskeleton and, upon ligand-induced aggregation, induces cell-type specific intracellular signal cascades. In an effort to define the mechanisms by which surface GalT exerts these intracellular effects, we used the yeast two-hybrid system to identify proteins that specifically interact with the GalT cytoplasmic domain. The yeast two-hybrid screen identified two distinct clones (1.12 and 2.52) that showed identity to portions of SSeCKS (Src Suppressed C Kinase Substrate). SSeCKS is a previously defined kinase and cytoskeleton scaffolding protein whose subcellular distribution and functions are remarkably similar to those attributed to GalT. Both SSeCKS and GalT have been localized to the perinuclear/Golgi region as well as to filopodia/lamellipodia. SSeCKS and GalT have been implicated in regulating cell growth, actin filament dynamics, and cell spreading. Interestingly, 1.12 and 2.52-GFP constructs were localized to subcellular domains that correlated with the two purported subcellular distributions for GalT; 2.52 being confined to the Golgi, whereas 1.12 localized primarily to filopodia. Coimmunoprecipitation assays demonstrate stable binding between the GalT cytoplasmic domain and the 1.12 and 2.52 domains of SSeCKS in appropriately transfected cells. Similar assays demonstrate binding between the endogenous GalT and SSeCKS proteins also. Coimmunoprecipitation assays were performed in both directions and produced similar results (i.e. using either anti-GalT domain or anti-SSeCKS domain antibodies as the precipitating reagent). A functional interaction between the GalT cytoplasmic domain and SSeCKS was illustrated by the ability of either the 1.12 or 2.52 SSeCKS domain to restore a normal adhesive phenotype in cells overexpressing the TL-GFP dominant negative construct. TL-GFP is composed of the GalT cytoplasmic and transmembrane domains fused to GFP, and leads to a loss of cell adhesion on laminin by displacing the endogenous GalT from its cytoskeleton binding sites. This is the first reported interaction between a glycosyltransferase and a scaffolding protein, and suggests that SSeCKS serve to integrate the various functions ascribed to the GalT cytoplasmic domain.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11493668     DOI: 10.1242/jcs.114.12.2291

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  24 in total

Review 1.  Cell surface beta1,4-galactosyltransferase function in mammary gland morphogenesis: insights from transgenic and knockout mouse models.

Authors:  Helen J Hathaway
Journal:  J Mammary Gland Biol Neoplasia       Date:  2003-10       Impact factor: 2.673

2.  Expression of beta-1,4-galactosyltransferase-I in rat during inflammation.

Authors:  Ji Qian; Chun Cheng; Haiou Liu; Jianping Chen; Meijuan Yan; Shuqiong Niu; Jing Qin; Linlin Sun; Lei Liu; Jianxin Gu; Aiguo Shen
Journal:  Inflammation       Date:  2007-02-15       Impact factor: 4.092

3.  Gravin regulates mesodermal cell behavior changes required for axis elongation during zebrafish gastrulation.

Authors:  Douglas C Weiser; Ujwal J Pyati; David Kimelman
Journal:  Genes Dev       Date:  2007-06-15       Impact factor: 11.361

4.  Developmental regulation of SSeCKS expression in rat brain.

Authors:  Li Chen; Jing Qin; Chun Cheng; Hai'ou Liu; Shuqiong Niu; Ji Qian; Linlin Sun; Feng Xiao; Shuxian Shi; Aiguo Shen
Journal:  J Mol Neurosci       Date:  2007       Impact factor: 3.444

5.  Gravin dynamics regulates the subcellular distribution of PKA.

Authors:  Xiaohong Yan; Magdalena Walkiewicz; Jennifer Carlson; Laura Leiphon; Bryon Grove
Journal:  Exp Cell Res       Date:  2009-01-13       Impact factor: 3.905

6.  The relationship between Src-suppressed C kinase substrate and β-1,4 galactosyltransferase-I in the process of lipopolysaccharide-induced TNF-α secretion in rat primary astrocytes.

Authors:  Bai Shao; Chunmiao Li; Huiguang Yang; Aiguo Shen; Xiaohong Wu; Qin Yuan; Xiujie Wu; Lihua Kang; Zhiqiang Liu; Guowei Zhang; Xiang Lu; Chun Cheng
Journal:  Cell Mol Neurobiol       Date:  2011-05-14       Impact factor: 5.046

7.  Molecular cloning, gene organization and expression of the human UDP-GalNAc:Neu5Acalpha2-3Galbeta-R beta1,4-N-acetylgalactosaminyltransferase responsible for the biosynthesis of the blood group Sda/Cad antigen: evidence for an unusual extended cytoplasmic domain.

Authors:  Maria-Dolores Montiel; Marie-Ange Krzewinski-Recchi; Philippe Delannoy; Anne Harduin-Lepers
Journal:  Biochem J       Date:  2003-07-15       Impact factor: 3.857

8.  Golgi phosphoprotein 3 determines cell binding properties under dynamic flow by controlling Golgi localization of core 2 N-acetylglucosaminyltransferase 1.

Authors:  Mohamed F Ali; Vishwanath B Chachadi; Armen Petrosyan; Pi-Wan Cheng
Journal:  J Biol Chem       Date:  2012-10-01       Impact factor: 5.157

Review 9.  Potential for therapeutic targeting of AKAP signaling complexes in nervous system disorders.

Authors:  Angela R Wild; Mark L Dell'Acqua
Journal:  Pharmacol Ther       Date:  2017-12-17       Impact factor: 12.310

10.  SSeCKS promoted lipopolysaccharide-sensitized astrocytes migration via increasing β-1,4-galactosyltransferase-I activity.

Authors:  Hua Wei; Leiting Xu; Chunmiao Li; Lianliang Liu; Derry Minyao Ng; Maria Haleem; Lingli Jiang; Ning Sun; Qingzhi Ling; Shaohua Ma; Lingli Zhang; Qinwen Wang; Tao Tao
Journal:  Neurochem Res       Date:  2019-01-31       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.